126 related articles for article (PubMed ID: 20390424)
1. Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.
Mete O; Kapran Y; Güllüoğlu MG; Kiliçaslan I; Erbil Y; Senyürek YG; Dizdaroğlu F
Virchows Arch; 2010 May; 456(5):515-21. PubMed ID: 20390424
[TBL] [Abstract][Full Text] [Related]
2. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique.
Pan CC; Chen PC; Tsay SH; Ho DM
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):347-52. PubMed ID: 16280664
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin expression in adrenocortical neoplasia: an immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular, and renal cell carcinoma.
Gaffey MJ; Traweek ST; Mills SE; Travis WD; Lack EE; Medeiros LJ; Weiss LM
Hum Pathol; 1992 Feb; 23(2):144-53. PubMed ID: 1371262
[TBL] [Abstract][Full Text] [Related]
4. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.
Avery AK; Beckstead J; Renshaw AA; Corless CL
Am J Surg Pathol; 2000 Feb; 24(2):203-10. PubMed ID: 10680888
[TBL] [Abstract][Full Text] [Related]
5. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors.
Renshaw AA; Granter SR
Mod Pathol; 1998 Dec; 11(12):1160-4. PubMed ID: 9872645
[TBL] [Abstract][Full Text] [Related]
6. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas.
Ghorab Z; Jorda M; Ganjei P; Nadji M
Appl Immunohistochem Mol Morphol; 2003 Dec; 11(4):330-3. PubMed ID: 14663359
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
Pan CC; Chen PC; Ho DM
Histopathology; 2004 Nov; 45(5):452-9. PubMed ID: 15500648
[TBL] [Abstract][Full Text] [Related]
8. Pax8, Napsin A, and CD10 as Immunohistochemical Markers of Canine Renal Cell Carcinoma.
Peat TJ; Edmondson EF; Miller MA; DuSold DM; Ramos-Vara JA
Vet Pathol; 2017 Jul; 54(4):588-594. PubMed ID: 28346124
[TBL] [Abstract][Full Text] [Related]
9. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.
Wang HY; Mills SE
Am J Surg Pathol; 2005 May; 29(5):640-6. PubMed ID: 15832088
[TBL] [Abstract][Full Text] [Related]
10. Clear cell meningioma: a clinicopathologic study of 18 tumors and examination of the use of CD10, CA9, and RCC antibodies to distinguish between clear cell meningioma and metastatic clear cell renal cell carcinoma.
Prayson RA; Chamberlain WA; Angelov L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):422-8. PubMed ID: 20453815
[TBL] [Abstract][Full Text] [Related]
11. SR-B1 and CD10 combined immunoprofile for differential diagnosis of metastatic clear cell renal cell carcinoma and clear cell carcinoma of the ovary.
Jiang T; Diao X; Ding M; Niu X; Wang C; Qi Y; Jia W; Pang L; Hu W; Zou H; Li F
J Mol Histol; 2021 Jun; 52(3):539-544. PubMed ID: 33608777
[TBL] [Abstract][Full Text] [Related]
12. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
14. [Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays].
Ortiz-Rey JA; Gómez De María C; Peláez Boismorand E; Fernández Costas A; Barbosa Barreiro MJ; Antón Badiola I
Actas Urol Esp; 2006 Mar; 30(3):281-6. PubMed ID: 16749584
[TBL] [Abstract][Full Text] [Related]
15. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.
Sangoi AR; Fujiwara M; West RB; Montgomery KD; Bonventre JV; Higgins JP; Rouse RV; Gokden N; McKenney JK
Am J Surg Pathol; 2011 May; 35(5):678-86. PubMed ID: 21490444
[TBL] [Abstract][Full Text] [Related]
17. CD10 is a diagnostic and prognostic marker in renal malignancies.
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
Histopathology; 2004 Nov; 45(5):460-7. PubMed ID: 15500649
[TBL] [Abstract][Full Text] [Related]
18. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.
Bakshi N; Kunju LP; Giordano T; Shah RB
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):310-5. PubMed ID: 17721277
[TBL] [Abstract][Full Text] [Related]
19. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma.
Chu P; Arber DA
Am J Clin Pathol; 2000 Mar; 113(3):374-82. PubMed ID: 10705818
[TBL] [Abstract][Full Text] [Related]
20. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration.
Fetsch PA; Powers CN; Zakowski MF; Abati A
Cancer; 1999 Jun; 87(3):168-72. PubMed ID: 10385449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
